Latest Therapies under investigation for multiple sclerosis Stories
An oral drug called ONO-4641 is under investigation because it can reduce the number of lesions in people with multiple sclerosis (MS).
Many of us have heard of or know someone with the dreadful disease known as multiple sclerosis. Affecting approximately 400,000 people in the United States and 2.5 million people worldwide, multiple sclerosis is still incurable and has few effective treatments available.
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.
Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) â€” a chronic inflammatory disease of the central nervous system.
EAST HANOVER, N.J., April 11, 2011 /PRNewswire/ -- A new analysis demonstrated that Gilenya(TM) (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.